Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations
The I-PREDICT strategy of maximizing personalized biomarker matching with individually dosed customized drug combinations enabled safe and active N-of-1 matched treatment, including regimens previously unstudied in Phase I trials. I-PREDICT represents a blueprint for a new personalized precision oncology paradigm, which merits validation via additional prospective trials.
Authors
- Michael E. Hahn (ORCID: https://orcid.org/0000-0002-8323-8174)
- Jason K. Sicklick (ORCID: https://orcid.org/0000-0003-4403-0271)
- Hitendra Patel (ORCID: https://orcid.org/0000-0001-8746-2600)
- Daisuke Nishizaki (ORCID: https://orcid.org/0000-0002-6746-3224)
- Mina Nikanjam (ORCID: https://orcid.org/0000-0001-7052-6348)
- Hirotaka Miyashita (ORCID: https://orcid.org/0000-0002-0433-9779)
- David Piccioni (ORCID: https://orcid.org/0000-0001-6006-0126)
- Ramez N. Eskander (ORCID: https://orcid.org/0000-0002-2101-1935)
- Scott M. Lippman (ORCID: https://orcid.org/0000-0002-1643-4124)
- Paul T. Fanta
- Ryosuke Okamura
- Shumei Kato
- J. Jack Lee
- Jeffrey S. Ross
- Rana R. McKay
- Razelle Kurzrock
Institutions
- Dartmouth College (US)
- The University of Texas MD Anderson Cancer Center (US)
- SUNY Upstate Medical University (US)
- Medical College of Wisconsin (US)
- UC San Diego Health System (US)
- University of California San Diego (US)
- Dartmouth Psychiatric Research Center (US)
- Kyoto University Hospital (JP)
- Foundation Medicine (United States)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1200/jco-25-01453
- Citations
- 3
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 74.45